Functional and Structural Characterization of Treatment-Emergent Nirmatrelvir Resistance Mutations at Low Frequencies in the Main Protease (Mpro) Reveals a Unique Evolutionary Route for SARS-CoV-2 to Gain Resistance - Takeaways - MDSpire

Functional and Structural Characterization of Treatment-Emergent Nirmatrelvir Resistance Mutations at Low Frequencies in the Main Protease (Mpro) Reveals a Unique Evolutionary Route for SARS-CoV-2 to Gain Resistance

  • By

  • Natalie M Deschenes

  • Jimena Pérez-Vargas

  • Zoe Zhong

  • Merrilee Thomas

  • Calem Kenward

  • Wesley A Mosimann

  • Liam J Worrall

  • Nicholas Waglechner

  • Angel XinLiu Li

  • Finlay Maguire

  • Patryk Aftanas

  • Jason R Smith

  • Jared Lim

  • Robert N Young

  • Artem Cherkasov

  • Lubna Farooqi

  • Adnan Moinuddin

  • Lina Siddiqi

  • Imaan Malik

  • Maxime Lefebvre

  • Mark Paetzel

  • Natalie C J Strynadka

  • François Jean

  • Allison McGeer

  • Robert A Kozak

  • June 3, 2025

  • 0 min

Share

  • 1

    The study identified low-frequency resistance mutations in the main protease (Mpro) of SARS-CoV-2 in patients treated with nirmatrelvir-ritonavir.

  • 2

    Two novel Mpro variants were discovered: D48D/L58F/P132H and D48D/L67V/K90R/P132H, which impact nirmatrelvir resistance without affecting Mpro activity.

  • 3

    Mutations were found in the Mpro N-terminal domain, disrupting substrate binding site structure and dynamics, potentially reducing protein stability.

  • 4

    This research highlights a unique evolutionary pathway for SARS-CoV-2 resistance, including cross-resistance to different Mpro inhibitors.

  • 5

    The findings emphasize the need for ongoing surveillance of low-frequency resistance mutations in clinical samples to inform therapeutic strategies.

Original Source(s)

Functional and Structural Characterization of Treatment-Emergent Nirmatrelvir Resistance Mutations at Low Frequencies in the Main Protease (Mpro) Reveals a Unique Evolutionary Route for SARS-CoV-2 to Gain Resistance

  • by Natalie M Deschenes, Jimena Pérez-Vargas, Zoe Zhong, Merrilee Thomas, Calem Kenward, Wesley A Mosimann, Liam J Worrall, Nicholas Waglechner, Angel XinLiu Li, Finlay Maguire, Patryk Aftanas, Jason R Smith, Jared Lim, Robert N Young, Artem Cherkasov, Lubna Farooqi, Adnan Moinuddin, Lina Siddiqi, Imaan Malik, Maxime Lefebvre, Mark Paetzel, Natalie C J Strynadka, François Jean, Allison McGeer, Robert A Kozak

  • June 3, 2025

Related Content

Early ICU Rehab Backed, With Caveats

Invited narrative review supports early, interprofessional rehabilitation across the ICU recovery continuum while emphasizing heterogeneous evidence and inconsistent implementation worldwide.

The CRISPR-powered Diagnostic SLEUTH

Novel DNA-guided system may support future RNA diagnostics and mutation detection

  • May 22, 2026

  • 2 min
FDA Monthly Preview: Key June Decisions to Watch

Several FDA decisions across multiple specialties are expected this month.